Last updated on December 2010

Phase 3 Randomized, Double-Blind Study of the Efficacy and Safety of 2 Doses of JAK-3, Compared to Methotrexate Naive patients with Rheumatoid Arthritis


Brief description of study

Phase 3 Randomized, Double-Blind Study of the Efficacy and Safety of 2 Doses of JAK-3, Compared to Methotrexate Naive patients with Rheumatoid Arthritis

Detailed Study Description

Do you have Rheumatoid arthritis? You may qualify to participate in a clinical research study.

JAK-3 inhibitors represent the first oral class of medication to have a demonstrable effect on a targeted component of the immune system. Seropositive rheumatoid arthritis patients are needed for this study. This double-blinded placebo controlled phase III trial is for a 2 year period, but does not limit patients to prior drug failures.

Clinical Study Identifier: TX135171

Contact Investigators or Research Sites near you

Start Over

The Center for Rheumatology and ...

The Center for Rheumatology and Bone Research
Wheaton, MD USA
  Connect »